Intimation of Results Presentation

  • This is a regulatory filing containing the Investor Presentation for Q4 and full year FY26 results ended March 31, 2026, submitted pursuant to Regulation 30 of SEBI LODR Regulations, 2015.
  • The presentation includes detailed financial performance, business updates, and strategic direction from management.
  • Mr. Jai Hiremath, Executive Chairman, provided commentary on the company's transition to sustainable growth phase with improved operational performance.

Financial Performance Overview

Q4 FY26 Consolidated Performance:

  • Revenue: Rs. 519 crores (QoQ growth: 5%, YoY decline: -6%)
  • EBITDA: Rs. 105 crores with margin of 20.3% (QoQ improvement of 356 bps, YoY decline of 205 bps)
  • PAT: Rs. 14 crores (including exceptional items)
  • Exceptional items: Rs. 47 crores impairment of manufacturing asset at Panoli

Full Year FY26 Performance:

  • Revenue: Rs. 1,713 crores (YoY decline: -8%)
  • EBITDA: Rs. 220 crores with margin of 12.9% (YoY decline: -33%)
  • PAT: Rs. -49 crores (including exceptional items of Rs. 85 crores)
  • Total Dividend: 30% for FY26 including final dividend of 20%

Segment-wise Performance Q4 FY26:

Pharmaceuticals:

  • Revenue: Rs. 292 crores (56% of total revenue)
  • EBIT: Rs. 35 crores
  • CDMO/Own Products split: 55%/45%
  • H2 FY26 Pharma Revenue grew 60% to Rs. 629 crores over H1 FY26
  • DMF filings increased to 5-6 annually versus 2-3 historically

Crop Protection:

  • Revenue: Rs. 228 crores (44% of total revenue)
  • EBIT: Rs. 39 crores
  • CDMO/Own Products split: 74%/26%
  • Quarterly growth: 45% QoQ and 13% YoY
  • H2 FY26 Crop Revenue grew 25% to Rs. 385 crores from H1 FY26

Strategic Business Updates

  • Pharmaceutical business recovery driven by resumption of customer offtake across own products and CDMO segments
  • Crop Protection business accelerated through volume increase despite competitive pricing environment
  • Strategic investments in high-potency laboratory at Pune R&D facility and pilot plant at Panoli are fully operational
  • Diversification into Personal Care and Specialty Chemicals segments progressing with expected FY27 contribution
  • Hikal Business Excellence framework delivering procurement savings, backward integration, and yield improvements

Manufacturing Capabilities

  • Total reactor volume across facilities: 2,307 m³
  • Jigani Unit 1: 615 m³ reactor volume, US FDA approved API facility
  • Jigani Unit 2: 93 m³ reactor volume, scale-up and launch plant
  • Panoli: 737 m³ reactor volume, US FDA approved site (acquired from Novartis)
  • Mahad: 549 m³ reactor volume, specialty chemicals and intermediates
  • Taloja: 593 m³ reactor volume, fungicides and insecticides

Additional Notes

  • The document includes the full investor presentation with detailed financial tables, balance sheet, cash flow statement, and operational metrics
  • The filing was digitally signed by Rajasekhar Reddy Chintakindi, Company Secretary & Compliance Officer on May 27, 2026